Loading
This study tests TROP-2-directed treatment; the registry reports that it is suspended.
The registry lists NCT07377526 as suspended, last updated 2026-07-31. Enrolment is 37 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells. Primary measures include Safety and Adverse Events (AEs). The registry reason for stopping is: PI Request No results are posted in the registry; this does not exclude separate publications. The title and brief summary specify intraperitoneal cells with oral belzutifan, but the intervention table incorrectly describes the cells as given by mouth; the route is not reproduced as a dosing recommendation.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/